108552
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
胰高血糖素样肽 - 2 作为肥胖儿童非酒精性脂肪肝病潜在生物标志物的初步评估：代谢关联及潜在机制研究
Authors Zhang SJ, Xu K, Zhu F, Teng YQ, Tang YF, Xu HW
Received 17 March 2025
Accepted for publication 9 September 2025
Published 18 September 2025 Volume 2025:18 Pages 3515—3525
DOI https://doi.org/10.2147/DMSO.S528780
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Mark D. DeBoer
Shu-Juan Zhang,1 Ke Xu,1 Feng Zhu,1 Yi-Qun Teng,1 Yan-Fei Tang,1 Hong-Wei Xu2
1Department of Pediatrics, The Second Hospital of Jiaxing, Jiaxing, 314000, People’s Republic of China; 2Department of Orthopedics, The Second Hospital of Jiaxing, Jiaxing, 314000, People’s Republic of China
Correspondence: Hong-Wei Xu, Department of Orthopedics, The Second Hospital of Jiaxing, No. 1518 of HuanCheng Bei Road, Nanhu District, Jiaxing, 314000, People’s Republic of China, Tel +86 13738261930, Email hongweixudrx@163.com
Objective: This study aimed to investigate the effects of glucagon-like peptide-2 (GLP-2) on insulin resistance and lipid metabolism, as well as potential mechanisms contributing to the development of non-alcoholic fatty liver disease (NAFLD) in children with obesity.
Methods: A cross-sectional study was conducted involving 107 children with obesity, aged between 5 and 15 years, including 55 with NAFLD and 52 without NAFLD. Anthropometric assessments and fasting blood samples were collected to evaluate GLP-2, plasma glucose, insulin (INS), lipids, leptin (LEP), and adiponectin (ADPN). Correlation and logistic regression analyses were performed to evaluate associations between GLP-2 and metabolic parameters.
Results: Children with NAFLD exhibited significantly higher levels of GLP-2, LEP, total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FPG), INS, and the homeostasis model assessment of insulin resistance index (HOMA-IR) (all p< 0.05), along with significantly lower levels of ADPN and high-density lipoprotein cholesterol (HDL-C) compared with those without NAFLD (p< 0.05). GLP-2 concentrations correlated positively with TC (r=0.42), TG (r=0.51), LDL-C (r=0.38), FPG (r=0.61), INS (r=0.58), HOMA-IR (r=0.61), and LEP (r=0.42), and negatively with ADPN (r=− 0.53; all p< 0.01). In univariate analysis, GLP-2 was identified as a risk factor for NAFLD (odds ratio [OR]=1.225, 95% confidence interval [CI]: 1.001– 1.499, p< 0.05); however, the association was attenuated after adjustment for body mass index (OR=1.112, p=0.102). ADPN retained a protective association (OR=0.771, p< 0.05).
Conclusion: GLP-2 may contribute to the pathophysiology of insulin resistance and dyslipidemia in pediatric NAFLD, potentially via modulation of adipokine activity. These findings suggest GLP-2 as a candidate biomarker and possible therapeutic target in this population.
Keywords: children, glucagon-like peptide-2, insulin resistance, lipid metabolism, non-alcoholic fatty liver disease, obesity
1Department of Pediatrics, The Second Hospital of Jiaxing, Jiaxing, 314000, People’s Republic of China; 2Department of Orthopedics, The Second Hospital of Jiaxing, Jiaxing, 314000, People’s Republic of China
Correspondence: Hong-Wei Xu, Department of Orthopedics, The Second Hospital of Jiaxing, No. 1518 of HuanCheng Bei Road, Nanhu District, Jiaxing, 314000, People’s Republic of China, Tel +86 13738261930, Email hongweixudrx@163.com
Objective: This study aimed to investigate the effects of glucagon-like peptide-2 (GLP-2) on insulin resistance and lipid metabolism, as well as potential mechanisms contributing to the development of non-alcoholic fatty liver disease (NAFLD) in children with obesity.
Methods: A cross-sectional study was conducted involving 107 children with obesity, aged between 5 and 15 years, including 55 with NAFLD and 52 without NAFLD. Anthropometric assessments and fasting blood samples were collected to evaluate GLP-2, plasma glucose, insulin (INS), lipids, leptin (LEP), and adiponectin (ADPN). Correlation and logistic regression analyses were performed to evaluate associations between GLP-2 and metabolic parameters.
Results: Children with NAFLD exhibited significantly higher levels of GLP-2, LEP, total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FPG), INS, and the homeostasis model assessment of insulin resistance index (HOMA-IR) (all p< 0.05), along with significantly lower levels of ADPN and high-density lipoprotein cholesterol (HDL-C) compared with those without NAFLD (p< 0.05). GLP-2 concentrations correlated positively with TC (r=0.42), TG (r=0.51), LDL-C (r=0.38), FPG (r=0.61), INS (r=0.58), HOMA-IR (r=0.61), and LEP (r=0.42), and negatively with ADPN (r=− 0.53; all p< 0.01). In univariate analysis, GLP-2 was identified as a risk factor for NAFLD (odds ratio [OR]=1.225, 95% confidence interval [CI]: 1.001– 1.499, p< 0.05); however, the association was attenuated after adjustment for body mass index (OR=1.112, p=0.102). ADPN retained a protective association (OR=0.771, p< 0.05).
Conclusion: GLP-2 may contribute to the pathophysiology of insulin resistance and dyslipidemia in pediatric NAFLD, potentially via modulation of adipokine activity. These findings suggest GLP-2 as a candidate biomarker and possible therapeutic target in this population.
Keywords: children, glucagon-like peptide-2, insulin resistance, lipid metabolism, non-alcoholic fatty liver disease, obesity